Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma

The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.

Trial Details

NCT ID
NCT06329869
Phase
PHASE2
Sponsor
National Taiwan University Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Sacituzumab govitecan
Locations (sample)
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Female or male patients, 18 years of age or older, able to understand and give written informed consent.
  • Histologically proven squamous cell carcinoma of esophagus.
  • Patients with advanced ESCC, defined as those with unresectable locally advanced, recurrent, or metastatic disease, failed prior platinum-based che…
  • Measurable disease as determined by RECIST 1.1. Lesions in previously irradiated areas should not be considered measurable unless they have progres…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →